The growth scan—typically performed between 28 and 32 weeks’ gestation—is a targeted ultrasound that assesses fetal size, amniotic fluid volume, placental position and appearance, and blood flow via Doppler. Unlike the anatomy scan at 18–22 weeks, this exam focuses on detecting deviations from expected growth trajectories, particularly small-for-gestational-age (SGA) or large-for-gestational-age (LGA) patterns. It is not routine for all pregnancies but is recommended for those with risk factors such as maternal hypertension, gestational diabetes, prior SGA birth, or suspected intrauterine growth restriction (IUGR). Accurate measurement of biparietal diameter (BPD), abdominal circumference (AC), and femur length (FL) allows clinicians to estimate fetal weight within ±10% using validated formulas like Hadlock’s. This article provides actionable, evidence-based information for expectant parents—grounded in ACOG, SMFM, and RCOG guidelines—and clarifies what each metric means, how it’s measured, and when follow-up is warranted.
When and Why the Growth Scan Is Scheduled
The optimal window for a dedicated growth scan is between 28 and 32 completed weeks of gestation. This timing balances biological necessity with technical feasibility: by week 28, fetal anatomy is sufficiently mature for reliable biometry, yet there remains enough time—roughly 8–12 weeks—to intervene if growth concerns emerge. Scans performed before 26 weeks lack sufficient predictive value for later growth patterns, while those after 34 weeks face increasing limitations due to fetal crowding, reduced amniotic fluid, and diminished acoustic windows. According to the Society for Maternal-Fetal Medicine (SMFM), growth scans are indicated in approximately 25–30% of pregnancies—not universally, but selectively based on clinical risk stratification.
Common indications include preexisting or gestational hypertension (e.g., preeclampsia diagnosed after 20 weeks), type 1 or type 2 diabetes managed with insulin, chronic kidney disease, autoimmune conditions like systemic lupus erythematosus (SLE), smoking ≥10 cigarettes/day, or a prior delivery of an infant <2,500 g without clear etiology. Notably, maternal obesity (BMI ≥30) alone does not mandate a growth scan unless accompanied by comorbidities; however, the American College of Obstetricians and Gynecologists (ACOG) recommends serial growth assessment starting at 28 weeks for BMI ≥35.
It is critical to understand that the growth scan is not a replacement for routine prenatal visits or fundal height measurements. Rather, it complements clinical assessment: fundal height should increase ~1 cm/week between 24–36 weeks. A discrepancy of >3 cm below expected (e.g., 28-week fundal height measuring 24 cm) triggers referral for growth ultrasound. Conversely, fundal height >3 cm above expected may signal polyhydramnios or macrosomia—but requires imaging confirmation.
Standardized Protocols Across Major Imaging Centers
Major academic medical centers—including Mayo Clinic, Cleveland Clinic, and Kaiser Permanente—follow standardized scanning protocols aligned with the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) guidelines. These require strict adherence to transducer positioning, caliper placement, and image magnification. For example, BPD must be measured on a true axial plane showing the thalamus and cavum septum pellucidum; AC must be obtained at the fetal liver level with stomach bubble and right branch of the portal vein visible; FL requires a neutral leg position with full bone visualization and no rotation. Technologists certified by the American Registry for Diagnostic Medical Sonography (ARDMS) perform >92% of these exams in accredited facilities.
Equipment matters. The GE Voluson E10 and Philips EPIQ 7 are FDA-cleared systems widely used in U.S. hospitals and outpatient imaging centers. Both offer automated biometry tools (e.g., GE’s AutoMeasure, Philips’ SmartTrack) that reduce inter-operator variability by up to 35%, per a 2023 multicenter validation study published in AJOG MFM. However, manual verification remains mandatory: automated outputs must be visually confirmed and adjusted if fetal position or shadowing compromises accuracy.
Key Biometric Measurements and Their Clinical Meaning
Three core measurements form the foundation of fetal growth assessment: biparietal diameter (BPD), abdominal circumference (AC), and femur length (FL). Each reflects distinct developmental processes. BPD approximates cranial growth and correlates strongly with gestational age early in pregnancy. AC reflects visceral mass, liver size, and subcutaneous fat deposition—making it the most sensitive indicator of nutritional status and placental function. FL tracks long-bone ossification and serves as a proxy for skeletal maturation.
Normal ranges are expressed as percentiles relative to population norms. Using the INTERGROWTH-21st standards—a globally validated dataset derived from low-risk pregnancies across eight countries—the 10th percentile for AC at 30 weeks is 25.8 cm, while the 90th percentile is 29.4 cm. A measurement below the 10th percentile warrants closer scrutiny; below the 3rd percentile meets formal criteria for SGA. Similarly, FL at 30 weeks averages 5.7 cm (±0.3 cm); values <5.2 cm raise concern for constitutional short stature or pathological growth delay.
Estimating Fetal Weight: Accuracy and Limitations
Fetal weight estimation (FWE) uses combinations of BPD, AC, and FL in regression formulas. The Hadlock formula—incorporating all three—is the most widely adopted in North America. At 32 weeks, an AC of 27.1 cm + FL of 5.8 cm + BPD of 7.9 cm yields an estimated fetal weight (EFW) of 1,740 g (±174 g). While highly useful, EFW has inherent limits: systematic overestimation occurs in fetuses with high body fat (e.g., infants of diabetic mothers), and underestimation is common in asymmetric IUGR where head sparing preserves BPD while AC lags.
Real-world accuracy data shows EFW error increases with gestational age. A meta-analysis of 12,487 ultrasounds found mean absolute percentage error (MAPE) was 7.2% at 28 weeks but rose to 10.8% at 36 weeks. Thus, a 3,200 g EFW at 36 weeks carries a 95% confidence interval of 2,850–3,550 g—not precise enough to definitively diagnose macrosomia (>4,000 g). Clinicians therefore rely on trends: two growth scans 2–3 weeks apart revealing a drop from 75th to 25th percentile in AC is more concerning than a single borderline EFW.
Amniotic Fluid and Placental Assessment
Amniotic fluid index (AFI) and single deepest pocket (SDP) are measured during the growth scan to evaluate fluid volume. AFI sums vertical pockets in four uterine quadrants; SDP identifies the largest vertical pocket free of cord or fetal parts. Normal AFI at 28–32 weeks ranges from 8–24 cm; SDP ranges from 2–8 cm. Oligohydramnios (AFI <5 cm or SDP <2 cm) occurs in ~3% of pregnancies and is associated with placental insufficiency, renal anomalies, or post-term gestation. Polyhydramnios (AFI >24 cm or SDP >8 cm) affects ~1–2% and may indicate fetal gastrointestinal obstruction, neurologic impairment, or maternal diabetes.
Placental grading—using the classic Grannum scale (Grade 0 to Grade III)—is assessed but carries limited utility for growth prediction. Grade III changes (e.g., calcifications, lobulation) appear normally after 36 weeks but do not correlate reliably with function. More clinically relevant is placental thickness: normal range is 2.0–3.5 cm at 30 weeks. Thickness <1.8 cm suggests hypoplasia; >4.0 cm may indicate edema or infection. Additionally, placental location is reconfirmed: a low-lying placenta (<2 cm from internal os) identified at 20 weeks often resolves spontaneously, but persistence at 32 weeks warrants repeat imaging at 36 weeks and discussion of delivery planning.
Doppler Ultrasound: Assessing Blood Flow Dynamics
Doppler interrogation of umbilical artery (UA), middle cerebral artery (MCA), and uterine arteries (UtA) adds functional insight beyond static measurements. UA pulsatility index (PI) reflects downstream placental resistance. At 30 weeks, normal UA-PI is 0.92 ± 0.18 (mean ± SD). Values >1.45 suggest elevated resistance and are associated with a 3.2-fold increased risk of SGA birth, per the 2022 PROGNOSIS trial. MCA-PI <1.28 indicates brain-sparing—a compensatory shift where blood flow is redirected to preserve cerebral perfusion amid placental compromise. UtA-PI >1.12 (with bilateral notching) predicts preeclampsia with 89% specificity, according to RCOG guidelines.
Doppler is not performed routinely in low-risk pregnancies. SMFM recommends it only when growth parameters are abnormal or maternal risk factors exist. Importantly, Doppler findings must be interpreted alongside biometry: isolated UA-PI elevation without AC reduction may reflect transient vasoconstriction rather than pathology, whereas combined UA-PI elevation + AC <10th percentile strongly supports diagnosis of severe IUGR.
Interpreting Results: Percentiles, Red Flags, and Next Steps
Results are reported using standardized percentiles derived from robust normative datasets. INTERGROWTH-21st and WHO fetal growth standards differ significantly: at 30 weeks, WHO places the 10th percentile for AC at 26.1 cm, while INTERGROWTH sets it at 25.8 cm—a 3 mm difference that may alter clinical classification. Most U.S. centers use INTERGROWTH due to its methodological rigor and inclusion of diverse ethnic groups.
Red flags prompting escalation include:
- AC <10th percentile with UA-PI >95th percentile
- EFW <10th percentile and falling across two scans
- AFI <5 cm with abnormal Doppler
- Placental thickness <1.8 cm + AC <5th percentile
When red flags emerge, care transitions to a maternal-fetal medicine (MFM) specialist. Frequency of monitoring intensifies: weekly growth scans plus non-stress tests (NST) or biophysical profiles (BPP) may begin at 32 weeks. Delivery timing is individualized—earlier intervention is considered if EFW drops below 1,500 g or Doppler abnormalities worsen. For uncomplicated SGA (no Doppler changes), delivery is typically planned at 37–38 weeks, balancing neonatal maturity against ongoing growth risks.
What Parents Can Do Before and After the Scan
Preparation impacts image quality. Patients are advised to drink 16–24 oz of water 45 minutes pre-scan to distend the bladder—this improves visualization of pelvic structures and fetal spine. Avoiding caffeine for 2 hours prior reduces fetal movement artifacts. Wearing a two-piece outfit facilitates quick access without full gowning.
After the scan, parents receive a written report containing all measurements, percentiles, EFW, AFI/SDP, placental grade and location, and Doppler indices (if performed). They should ask three questions: (1) “Is my baby growing along its expected curve—or has it crossed percentiles?” (2) “Are the amniotic fluid and placenta functioning normally?” (3) “What’s the plan if things change before my next visit?” Documenting answers in a shared digital note (e.g., Apple Health or MyChart) helps track trends.
Technology, Training, and Quality Assurance
Ultrasound quality varies significantly across settings. Accredited labs—certified by the American Institute of Ultrasound in Medicine (AIUM)—undergo biannual peer review of 25 random exams per technologist. AIUM standards mandate minimum equipment specifications: transducers must operate at 3.5–5 MHz for abdominal scanning, and machines must display real-time frame rates ≥25 fps to capture fetal motion accurately. Facilities using outdated hardware (e.g., GE Logiq E9 pre-2016 firmware) show 22% higher measurement variability, per a 2021 AIUM audit.
Technologist training is equally vital. ARDMS credentialing requires 12 months of supervised scanning and passing a 200-question exam covering physics, instrumentation, and obstetric pathology. Yet only 68% of community-based clinics employ fully credentialed sonographers, compared to 94% in academic centers. When selecting a facility, parents should verify AIUM accreditation and ask whether technologists hold RDMS (Registered Diagnostic Medical Sonographer) credentials with OB/GYN specialty.
Navigating Anxiety and Communicating with Your Care Team
It’s normal to feel anxious before a growth scan—especially if prior pregnancies involved complications. Studies show 41% of parents report elevated stress during targeted ultrasounds, often misinterpreting terms like “borderline” or “trend downward” as definitive diagnoses. Remember: a single measurement near a percentile cutoff is not diagnostic. Growth is dynamic; many fetuses fluctuate ±10 percentile points naturally over 2 weeks.
Effective communication starts with framing questions collaboratively. Instead of “Is something wrong?”, try “Can you help me understand what this AC measurement tells us about how my baby is using nutrients?” or “If we repeat this in 10 days, what change would reassure you?” Providers respond best to curiosity paired with clarity about personal priorities—e.g., “I want to avoid early delivery unless absolutely necessary, so what signs would make that the safest choice?”
Support resources matter. The March of Dimes offers free webinars on interpreting ultrasound reports. Local hospital-based perinatal support groups (e.g., UCLA’s Prenatal Wellness Circle) provide peer-led discussions led by licensed clinical social workers. Apps like Ovia Pregnancy log fundal height and symptom trends—data that, when shared with providers, strengthens shared decision-making.
Evidence-Based Interventions for Suboptimal Growth
When growth concerns arise, interventions are tiered by severity. For mild AC slowing (e.g., 25th → 15th percentile over 2 weeks), conservative measures include optimized nutrition (≥2,200 kcal/day with 75–100 g protein), daily fetal movement counting (kick counts ≥10 in 2 hours), and twice-weekly home blood pressure monitoring. For moderate concern (AC <10th percentile + normal Doppler), low-dose aspirin (81 mg/day) is continued if initiated at <16 weeks; if not, initiation is generally not beneficial after 28 weeks.
No supplement regimen has proven efficacy for reversing IUGR. Meta-analyses confirm that omega-3 fatty acids, zinc, or vitamin D supplementation do not improve EFW or reduce SGA rates in well-nourished populations. However, for women with documented micronutrient deficiencies (e.g., serum ferritin <30 ng/mL), iron repletion restores placental transferrin receptor expression—potentially improving nutrient transport. Always coordinate supplementation with your OB-GYN or MFM specialist.
Real-World Data: Outcomes and Follow-Up
Longitudinal data from the NICHD Fetal Growth Studies shows that 78% of fetuses identified as SGA at 32 weeks reach appropriate weight by term without intervention—highlighting the importance of avoiding premature labeling. Of those delivered early for growth concerns, 86% have no significant neonatal complications, and 92% achieve catch-up growth by age 2 years.
Table 1 summarizes key metrics and thresholds used in clinical decision-making:
| Metric | 30 Weeks Normal Range | Clinical Threshold | Associated Risk (vs. Normal) |
|---|---|---|---|
| Abdominal Circumference (AC) | 25.8–29.4 cm (10th–90th %) | <25.8 cm | 4.1× higher risk of SGA birth |
| Estimated Fetal Weight (EFW) | 1,380–1,790 g | <1,380 g | 3.7× higher NICU admission rate |
| Umbilical Artery PI | 0.74–1.10 | >1.45 | 3.2× higher risk of cesarean for non-reassuring FHR |
| Amniotic Fluid Index (AFI) | 8–24 cm | <5 cm | 2.8× higher risk of cord compression |
| Placental Thickness | 2.0–3.5 cm | <1.8 cm | 5.3× higher risk of preterm birth <34 weeks |
Follow-up extends beyond delivery. Pediatricians screen for metabolic health at 6, 12, and 24 months—monitoring BMI trajectory, blood pressure, and fasting glucose. Children born SGA have a 1.8-fold increased lifetime risk of type 2 diabetes; early lifestyle counseling significantly mitigates this. Likewise, parents who experienced growth-related complications benefit from postpartum cardiovascular risk assessment—hypertension and dyslipidemia screening at 6–12 weeks post-delivery is standard of care per ACOG.
Growth scans are not predictors of intelligence, temperament, or long-term development. A 2023 cohort study tracking 1,842 children born SGA found no differences in Bayley-III cognitive scores at age 3 compared to matched controls, reinforcing that growth velocity reflects physiology—not potential. Parental presence, responsive caregiving, and enriched language exposure remain the strongest modifiable influences on neurodevelopment—regardless of birth weight.
Finally, remember that growth scans serve one purpose: to inform timely, personalized care. They are tools—not verdicts. Every measurement exists within a broader context of maternal health, fetal behavior, and clinical judgment. When interpreted thoughtfully and communicated compassionately, they empower families to participate actively in decisions that shape both immediate safety and lifelong wellness.
